Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis.

Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis.

Eosinophilic bronchitis is a common cause of chronic cough, characterized by sputum eosinophilia similar to that seen in asthma, but unlike asthma the patients have no objective evidence of variable airflow obstruction or airway hyperresponsiveness. The reason for the different functional associatio...

Descripció completa

Dades bibliogràfiques
Autors principals:	Brightling, C, Ward, R, Wardlaw, A, Pavord, I
Format:	Journal article
Idioma:	English
Publicat:	2000

Ítems similars

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
per: Brightling, C, et al.
Publicat: (2003)

Eosinophilic bronchitis is an important cause of chronic cough.
per: Brightling, C, et al.
Publicat: (1999)

The significance of eosinophilic airway inflammation in asthma
per: Pavord, I, et al.
Publicat: (2002)

Eosinophilic bronchitis: an important cause of prolonged cough.
per: Brightling, C, et al.
Publicat: (2000)

Eosinophils in asthma and airway hyperresponsiveness.
per: Brightling, C, et al.
Publicat: (2004)

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.
per: Kulkarni, N, et al.
Publicat: (2010)

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.
per: Berry, M, et al.
Publicat: (2005)

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
per: Siva, R, et al.
Publicat: (2007)

Eosinophilic bronchitis - what is it and why is it important?
per: Brightling, C, et al.
Publicat: (2000)

Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma.
per: Brightling, C, et al.
Publicat: (1999)

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness.
per: Green, R, et al.
Publicat: (2006)

Observational study of the natural history of eosinophilic bronchitis.
per: Berry, M, et al.
Publicat: (2005)

Ozone Inhalation Attenuated the Effects of Budesonide on Aspergillus fumigatus-Induced Airway Inflammation and Hyperreactivity in Mice
per: Cameron H. Flayer, et al.
Publicat: (2019-09-01)

Eosinophil Inflammation and Hyperresponsiveness in the Airways as Phenotypes of COPD, and Usefulness of Inhaled Glucocorticosteroids
per: Hiroaki Kume, et al.
Publicat: (2019-07-01)

Asthma control, airway responsiveness and airway inflammation.
per: Pavord, I
Publicat: (2009)

Eosinophilic bronchitis: clinical features, management and pathogenesis.
per: Birring, S, et al.
Publicat: (2003)

New insights into the relationship between airway inflammation and asthma.
per: Wardlaw, A, et al.
Publicat: (2002)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
per: Berry, M, et al.
Publicat: (2007)

Eosinophilic phenotypes of airway disease.
per: Pavord, I
Publicat: (2013)

Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control.
per: Barnes, N, et al.
Publicat: (2007)

Eosinophils in Asthma and Airway Hyperresponsiveness [3] (multiple letters)
per: Brightling, C, et al.
Publicat: (2004)

Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis.
per: Siddiqui, S, et al.
Publicat: (2007)

Chapter 11. Mast cell localization within the airway smooth muscle: Relationship to airway hyperresponsiveness and other asthma phenotypes
per: Wardlaw, A, et al.
Publicat: (2004)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma.
per: Brightling, C, et al.
Publicat: (2000)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma
per: Brightling, C, et al.
Publicat: (2000)

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol.
per: Pavord, I, et al.
Publicat: (2009)

TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis.
per: Brightling, C, et al.
Publicat: (2002)

Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis.
per: Berry, M, et al.
Publicat: (2004)

Outcomes of Holmium Laser, Cryoablation, and Budesonide Inhalation for Treating Severe Central Airway Stenosis in Infants
per: Lei Zhang, et al.
Publicat: (2023-12-01)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
per: Shrimanker, R, et al.
Publicat: (2017)

Airway hyperresponsiveness is dissociated from airway wall structural remodeling.
per: Siddiqui, S, et al.
Publicat: (2008)

Airways Disease: Phenotyping Heterogeneity Using Measures of Airway Inflammation
per: Siddiqui Salman, et al.
Publicat: (2007-06-01)

Association between neutrophilic airway inflammation and airflow limitation in adults with asthma.
per: Shaw, D, et al.
Publicat: (2007)

Role of eosinophilic airway inflammation in models of asthma
per: José R Lapa e Silva, et al.
Publicat: (1997-12-01)

Increased Levels of Airway Neutrophils Reduces the Inhibitory Effects of Inhaled Glucocorticosteroids on Allergen-Induced Airway Eosinophils
per: Gail M Gauvreau, et al.
Publicat: (2002-01-01)

IL-13 expression by blood T cells and not eosinophils is increased in asthma compared to non-asthmatic eosinophilic bronchitis
per: Mistry Vijay, et al.
Publicat: (2009-07-01)

Multiple inflammatory hits and the pathogenesis of severe airway disease.
per: Pavord, I, et al.
Publicat: (2006)

Mast-cell infiltration of airway smooth muscle in asthma.
per: Brightling, C, et al.
Publicat: (2002)

The A to E of airway disease.
per: Pavord, I, et al.
Publicat: (2010)

Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
per: Hirofumi Watanabe, et al.
Publicat: (2020-10-01)